Michael Khalil

Prof. Dr. Michael Khalil

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2018 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
MKMichael Khalil
Michael Khalil
CTCharlotte E. Teunissen
Charlotte E. Teunissen
MOMarkus Otto
Markus Otto
FPFredrik Piehl
Fredrik Piehl
MSMaria Pia Sormani
Maria Pia Sormani
JKJens Kuhle
Jens Kuhle

10 February 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
MKMichael Khalil
Michael Khalil
LPLukas Pirpamer
Lukas Pirpamer
EHEdith Hofer
Edith Hofer
MVMargarete M. Voortman
Margarete M. Voortman
CBChristian Barro
Christian Barro
JKJens Kuhle
Jens Kuhle
Neurofilament light (NfL) protein is a marker of neuro-axonal damage and can be measured not only in cerebrospinal fluid but also in serum, which allows for repeated assessments. There is still limited knowledge regarding the association of serum NfL (sNfL) with age and subclinical morphologic brain changes and their dynamics in the normal population. We measured sNfL by a single molecule array (Simoa) assay in 335 individuals participating in a population-based cohort study and after a mean follow-up time of 5.9 years (n = 103). Detailed clinical examination, cognitive testing and 3T brain MRI were performed to assess subclinical brain damage. We show that rising and more variable sNfL in individuals >60 years indicate an acceleration of neuronal injury at higher age, which may be driven by subclinical comorbid pathologies. This is supported by a close association of sNfL with brain volume changes in a cross-sectional and especially longitudinal manner.

12 April 2024 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
MKMichael Khalil
Michael Khalil
CTCharlotte E. Teunissen
Charlotte E. Teunissen
SLSylvain Lehmann
Sylvain Lehmann
MOMarkus Otto
Markus Otto
FPFredrik Piehl
Fredrik Piehl
JKJens Kuhle
Jens Kuhle

1 January 2017 in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Verified
Journal Article
Open access
SESebastiaan Engelborghs
Sebastiaan Engelborghs
ENEllis Niemantsverdriet
Ellis Niemantsverdriet
HSHanne Struyfs
Hanne Struyfs
KBKaj Blennow
Kaj Blennow
RBRaf Brouns
Raf Brouns
CTCharlotte E. Teunissen
Charlotte E. Teunissen
Introduction: Cerebrospinal fluid collection by lumbar puncture (LP) is performed in the diagnostic workup of several neurological brain diseases. Reluctance to perform the procedure is among others due to a lack of standards and guidelines to minimize the risk of complications, such as post‐LP headache or back pain.Methods: We provide consensus guidelines for the LP procedure to minimize the risk of complications. The recommendations are based on (1) data from a large multicenter LP feasibility study (evidence level II‐2), (2) systematic literature review on LP needle characteristics and post‐LP complications (evidence level II‐2), (3) discussion of best practice within the Joint Programme Neurodegenerative Disease Research Biomarkers for Alzheimer's disease and Parkinson's Disease and Biomarkers for Multiple Sclerosis consortia (evidence level III).Results: Our consensus guidelines address contraindications, as well as patient‐related and procedure‐related risk factors that can influence the development of post‐LP complications.Discussion: When an LP is performed correctly, the procedure is well tolerated and accepted with a low complication rate.

1 May 2013 in Radiology
Verified
Journal Article
Closed access
CLChristian Langkammer
Christian Langkammer
TLTian Liu
Tian Liu
MKMichael Khalil
Michael Khalil
CEChristian Enzinger
Christian Enzinger
MJMargit Jehna
Margit Jehna
SRStefan Ropele
Stefan Ropele
We have showed that quantitative susceptibility mapping has superior sensitivity in the assessment of multiple sclerosis-related tissue changes in the basal ganglia than does R2* relaxation rate ma... PurposeTo apply quantitative susceptibility mapping (QSM) in the basal ganglia of patients with multiple sclerosis (MS) and relate the findings to R2* mapping with regard to the sensitivity for cli...

13 February 2015 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
JKJ Kuhle
J Kuhle
GDG Disanto
G Disanto
RDR Dobson
R Dobson
RAR Adiutori
R Adiutori
LBL Bianchi
L Bianchi
GGGavin Giovannoni
Gavin Giovannoni
Background and objective: We explored which clinical and biochemical variables predict conversion from clinically isolated syndrome (CIS) to clinically definite multiple sclerosis (CDMS) in a large international cohort. Methods: Thirty-three centres provided serum samples from 1047 CIS cases with at least two years’ follow-up. Age, sex, clinical presentation, T2-hyperintense lesions, cerebrospinal fluid (CSF) oligoclonal bands (OCBs), CSF IgG index, CSF cell count, serum 25-hydroxyvitamin D3 (25-OH-D), cotinine and IgG titres against Epstein-Barr nuclear antigen 1 (EBNA-1) and cytomegalovirus were tested for association with risk of CDMS. Results: At median follow-up of 4.31 years, 623 CIS cases converted to CDMS. Predictors of conversion in multivariable analyses were OCB (HR = 2.18, 95% CI = 1.71–2.77, p < 0.001), number of T2 lesions (two to nine lesions vs 0/1 lesions: HR = 1.97, 95% CI = 1.52–2.55, p < 0.001; >9 lesions vs 0/1 lesions: HR = 2.74, 95% CI = 2.04–3.68, p < 0.001) and age at CIS (HR per year inversely increase = 0.98, 95% CI = 0.98–0.99, p < 0.001). Lower 25-OH-D levels were associated with CDMS in univariable analysis, but this was attenuated in the multivariable model. OCB positivity was associated with higher EBNA-1 IgG titres. Conclusions: We validated MRI lesion load, OCB and age at CIS as the strongest independent predictors of conversion to CDMS in this multicentre setting. A role for vitamin D is suggested but requires further investigation.